The UK and US have hammered out a landmark commercial pact that will keep no tariffs on UK pharmaceutical exports being sold in the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to raise spending on pharmaceuticals through the NHS. This commitment guarantees that duties on these vital products will stay at zero for a duration of the next three years.
This development follows previous warnings to hike duties on branded drug imports, with increases mentioned as high as double the cost.
"This deal with the United Kingdom reinforces the international landscape for innovative medicines and brings long-overdue equity to transatlantic pharmaceutical trade," a statement declared.
Trade Significance
Medicines are one of the the United Kingdom's biggest exports to the America, which is by far the biggest destination for leading UK drugmakers.
Export figures show that in the one-year period to the end of last September, the UK shipped pharmaceutical products totaling billions to the US. This figure represented 17.4% of British export trade in that timeframe.
"This deal safeguards employment, stimulates funding and facilitates the UK to establish itself as a global hub for life sciences," a government official commented.
Specific NHS Changes
The deal includes several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to raise overall NHS spending on medicines from 0.3% of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, repayments topped 20%.
Broader Context
This agreement takes place against a long-running dispute between the sector and the ministers over medicine costs and approval rates.
This friction were intensified by assertions that American customers were charged a premium for the equivalent treatments than consumers in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been pledged toward US facilities.
A senior figure stated that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the last ten years.
